Affymetrix said today it will postpone consideration of Thermo Fisher Scientific’s $1.3 billion acquisition offer for a week while considering a revised offer made for the company yesterday by ...

Shares of Affymetrix plummeted $9.87 to $18.13. Citing a slowdown in spending by biotech firms and universities, Affymetrix said late Thursday it wouldn't meet earlier first-quarter revenue and ...

Affymetrix Inc. on Wednesday postponed a vote on its proposed tie-up with Thermo Fisher Scientific Inc., TMO -1.64% saying a new unsolicited bid from Origin Technologies Corp. could reasonably ...

Affymetrix, best known for its pioneering work in commercializing microarrays for gene expression research since the early 1990s, has grown to become much more than a microarray innovator. Through ...

Shares of Affymetrix AFFX tumbled 17 percent in after-hours trading Thursday after the biotech firm warned that first-quarter revenue and profit would be lower than expected. Affymetrix said it ...

Thermo Fisher Scientific Inc. TMO -0.58% will buy Affymetrix Inc. in a roughly $1.3 billion cash deal that would boost its biogenetic analysis portfolio, the company said Friday. Under the terms ...

Affymetrix, Inc., (NASDAQ:AFFX) today announced that it has signed a definitive agreement to acquire eBioscience, Inc., a privately-held San Diego, CA ...

Affymetrix Inc. (Nasdaq:AFFX) announced today that it has entered into a definitive agreement to acquire Panomics Inc., a privately held Fremont, ...

Affymetrix lost $21.5 million, or 38 cents, compared with $5.5 million, or 10 cents, in the quarter a year earlier. Revenue rose 70%, to $59.4 million from $34.9 million.

Affymetrix CEO opens his walletFor the first time since the company he co-founded went public in 1996, Affymetrix Chief Executive Stephen Fodor bought its shares on the open market. He paid ...